Results 1 to 10 of about 44,829 (223)

Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor [PDF]

Frontiers in Immunology, 2021
Tumorigenesis is a complex multifactorial and multistep process in which tumors can utilize a diverse repertoire of immunosuppressive mechanisms to evade host immune attacks.
Xiaotian Song, Xiaotian Song, Qianqian Si, Qianqian Si, Rui Qi, Rui Qi, Weidan Liu, Miao Li, Miao Li, Mengyue Guo, Mengyue Guo, Lin Wei, Lin Wei, Zhiyan Yao, Zhiyan Yao   +14 more
doaj   +3 more sources

The role of indoleamine 2,3-dioxygenase 1 in early-onset post-stroke depression [PDF]

Frontiers in Immunology, 2023
BackgroundThe immune-inflammatory response has been widely considered to be involved in the pathogenesis of post-stroke depression (PSD), but there is ambiguity about the mechanism underlying such association.MethodsAccording to Diagnostic and ...
Hengshu Chen, Xia Huang, Chang Zeng, Dongren Sun, Fan Liu, Jingyuan Zhang, Qiao Liao, Shihang Luo, Weiye Xu, Yeqing Xiao, Danfeng Zeng, Mingyu Song, Mingyu Song, Fafa Tian   +13 more
doaj   +3 more sources

Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells [PDF]

Haematologica, 2010
Background The immunoregulatory enzyme indoleamine 2,3-dioxygenase, which catalyzes the conversion of tryptophan into kynurenine, is expressed in a significant subset of patients with acute myeloid leukemia, resulting in the inhibition of T-cell ...
Antonio Curti, Sara Trabanelli, Chiara Onofri, Michela Aluigi, Valentina Salvestrini, Darina Ocadlikova, Cecilia Evangelisti, Sergio Rutella, Raimondo De Cristofaro, Emanuela Ottaviani, Michele Baccarani, Roberto M. Lemoli   +11 more
doaj   +5 more sources

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

Journal of Hematology & Oncology, 2021
Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme enzyme that catalyzes the oxidation of L-tryptophan. Functionally, IDO1 has played a pivotal role in cancer immune escape via catalyzing the initial step of the kynurenine pathway, and overexpression of IDO1
Kai Tang, Ya-Hong Wu, Yihui Song, Bin Yu
doaj   +2 more sources

Laeverin/aminopeptidase Q induces indoleamine 2,3-dioxygenase-1 in human monocytes [PDF]

iScience, 2023
Summary: Human extravillous trophoblast (EVT) invades the maternal endometrium and reconstructs uterine spiral arteries cooperatively with maternal immune cells. Although EVT has allogeneic paternal antigens, the maternal immune system does not reject it.
Takuma Suzuki, Takashi Iizuka, Kyosuke Kagami, Takeo Matsumoto, Rena Yamazaki, Takiko Daikoku, Akihito Horie, Masanori Ono, Akira Hattori, Hiroshi Fujiwara   +9 more
doaj   +2 more sources

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past

Journal of Experimental & Clinical Cancer Research, 2021
Indoleamine 2,3-dioxygenase 1 (IDO1), a monomeric heme-containing enzyme, catalyzes the first and rate-limiting step in the kynurenine pathway of tryptophan metabolism, which plays an important role in immunity and neuronal function.
Yu Yao, Heng Liang, Xin Fang, Shengnan Zhang, Zikang Xing, Lei Shi, Chunxiang Kuang, Barbara Seliger, Qing Yang   +8 more
doaj   +2 more sources

Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma. [PDF]

J Med Chem, 2022
Indoleamine 2,3-dioxygenase 1 (IDO1) is a potent immunosuppressive enzyme that inhibits the antitumor immune response through both tryptophan metabolism and non-enzymatic functions.
Bollu LR, Bommi PV, Monsen PJ, Zhai L, Lauing KL, Bell A, Kim M, Ladomersky E, Yang X, Platanias LC, Matei DE, Bonini MG, Munshi HG, Hashizume R, Wu JD, Zhang B, James CD, Chen P, Kocherginsky M, Horbinski C, Cameron MD, Grigorescu AA, Yamini B, Lukas RV, Schiltz GE, Wainwright DA.   +25 more
europepmc   +2 more sources

Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1

Nature Communications, 2017
Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an immunotherapeutic target for cancer therapy. Here, the authors present the substrate-, inhibitor- and effector-bound hIDO1 crystal structures, which give insights into the mechanism and reveal a second ...
Ariel Lewis-Ballester, Khoa N. Pham, Dipanwita Batabyal, Shay Karkashon, Jeffrey B. Bonanno, Thomas L. Poulos, Syun-Ru Yeh   +6 more
doaj   +2 more sources

Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1. [PDF]

Signal Transduct Target Ther, 2022
Indoleamine 2,3-dioxygenase 1 (IDO1), the enzyme that catabolizes tryptophan (Trp) metabolism to promote regulatory T cells (Tregs) and suppress CD8 + T cells, is regulated by several intrinsic signaling pathways.
Liang F, Wang GZ, Wang Y, Yang YN, Wen ZS, Chen DN, Fang WF, Zhang B, Yang L, Zhang C, Han SC, Yang FY, Wang D, Liang LJ, Wang Z, Zhao Y, Wang CL, Zhang L, Zhou GB.   +18 more
europepmc   +2 more sources

Indoleamine-2,3-Dioxygenase 1 Deficiency Suppresses Seizures in Epilepsy

Frontiers in Cellular Neuroscience, 2021
Background: Indoleamine-2,3-dioxygenase 1 (IDO1) is the initial and rate-limiting enzyme in the metabolism of tryptophan (TRP) to kynurenine (KYN).
Ning Deng, Jiao Hu, Yu Hong, Yu Hong, Yuewen Ding, Yuewen Ding, Yifan Xiong, Zhiyong Wu, Zhiyong Wu, Wei Xie, Wei Xie   +10 more
doaj   +2 more sources